Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Janumet (sitagliptin and metformin HCl) by Year
Janumet (sitagliptin and metformin HCl) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)
Merck Janumet (sitagliptin and metformin HCl): 2.0% in FY2025, up 18.0 pts from a year earlier. That is the highest of the 8 years on record here.
Where the FY2025 figure comes from
“|| Janumet | 247 | 251 | 243 | 199 | 940 | 251 | 224 | 204 | 255 | 935 | -22 | -22 | 1 | 2”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Janumet (sitagliptin and metformin HCl) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.0% | +18.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -16.0% | +13.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | -29.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | -3.0% | -1.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | -2.0% | +3.0 pts | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | -5.0% | -7.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 2.0% | +5.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | -3.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Janumet (sitagliptin and metformin HCl) (%), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-janumet-ww-exfx-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.